Th17 plasticity and its relevance to inflammatory bowel disease

Journal of Autoimmunity

Volumn 87, Issue , 2018, Pages 38-49

  Ueno, Aito ^a,b   Jeffery, Louisa ^c   Kobayashi, Taku ^b   Hibi, Toshifumi ^b   Ghosh, Subrata ^c   Jijon, Humberto ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b KITASATO INSTITUTE HOSPITAL   (Japan)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Diet; Ikaros family; Inflammatory bowel disease; Microbiota; Text; Th17 plasticity

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CD8 ANTIGEN; IKAROS TRANSCRIPTION FACTOR; IKAROS TRANSCRIPTION FACTOR 1; IKAROS TRANSCRIPTION FACTOR 2; IKAROS TRANSCRIPTION FACTOR 3; IKAROS TRANSCRIPTION FACTOR 4; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17; NICOTINAMIDE; RETINOL; SHORT CHAIN FATTY ACID; TRYPTOPHAN; UNCLASSIFIED DRUG; VITAMIN D;

BIOLOGICAL THERAPY; CELL HETEROGENEITY; CELL MATURATION; CELL PLASTICITY; CELL TRANSDIFFERENTIATION; DIETARY INTAKE; ENERGY RESOURCE; ENVIRONMENTAL FACTOR; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE MUCOSA; LYMPHOCYTE SUBPOPULATION; LYMPHOID CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH1 CELL LINE; TH17 CELL; TH22 CELL; ANIMAL; CELL DIFFERENTIATION; HOMEOSTASIS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MOUSE;

ANIMALS; CELL DIFFERENTIATION; CELL PLASTICITY; CELL TRANSDIFFERENTIATION; GASTROINTESTINAL MICROBIOME; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICE; TH17 CELLS;

EID: 85039556211     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2017.12.004     Document Type: Review

References (151)

1. Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., Benchimol, E.I., Panaccione, R., Ghosh, S., Barkema, H.W., Kaplan, G.G., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142(1), 2012 46–54.e42.
2. Zenewicz, L.A., Antov, A., Flavell, R.A., CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol. Med. 15:5 (2009), 199–207.
3. Sartor, R.B., Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am. J. Gastroenterol. 92:12 Suppl (1997), 5s–11s.
4. Skamnelos, A., Tatsioni, A., Katsanos, K.H., Tsianos, V., Christodoulou, D., Tsianos, E.V., CD4 count remission hypothesis in patients with inflammatory bowel disease and human immunodeficiency virus infection: a systematic review of the literature. Ann. Gastroenterol. 28:3 (2015), 337–346.
5. Kamanaka, M., Huber, S., Zenewicz, L.A., Gagliani, N., Rathinam, C., O'Connor, W. Jr., Wan, Y.Y., Nakae, S., Iwakura, Y., Hao, L., Flavell, R.A., Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J. Exp. Med. 208:5 (2011), 1027–1040.
6. Ordas, I., Eckmann, L., Talamini, M., Baumgart, D.C., Sandborn, W.J., Ulcerative colitis. Lancet (London, England) 380:9853 (2012), 1606–1619.
7. Baumgart, D.C., Sandborn, W.J., Crohn's disease. Lancet (London, England) 380:9853 (2012), 1590–1605.
8. Brand, S., Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58:8 (2009), 1152–1167.
9. Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T., Fujiyama, Y., Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52:1 (2003), 65–70.
10. Jiang, W., Su, J., Zhang, X., Cheng, X., Zhou, J., Shi, R., Zhang, H., Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. [et al.] Inflamm. Res. Off. J. Europ. Histamine Res. Soc. 63:11 (2014), 943–950.
11. Sugihara, T., Kobori, A., Imaeda, H., Tsujikawa, T., Amagase, K., Takeuchi, K., Fujiyama, Y., Andoh, A., The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin. Exp. Immunol. 160:3 (2010), 386–393.
12. Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., Lee, J.C., Schumm, L.P., Sharma, Y., Anderson, C.A., Essers, J., Mitrovic, M., Ning, K., Cleynen, I., Theatre, E., Spain, S.L., Raychaudhuri, S., Goyette, P., Wei, Z., Abraham, C., Achkar, J.P., Ahmad, T., Amininejad, L., Ananthakrishnan, A.N., Andersen, V., Andrews, J.M., Baidoo, L., Balschun, T., Bampton, P.A., Bitton, A., Boucher, G., Brand, S., Buning, C., Cohain, A., Cichon, S., D'Amato, M., De Jong, D., Devaney, K.L., Dubinsky, M., Edwards, C., Ellinghaus, D., Ferguson, L.R., Franchimont, D., Fransen, K., Gearry, R., Georges, M., Gieger, C., Glas, J., Haritunians, T., Hart, A., Hawkey, C., Hedl, M., Hu, X., Karlsen, T.H., Kupcinskas, L., Kugathasan, S., Latiano, A., Laukens, D., Lawrance, I.C., Lees, C.W., Louis, E., Mahy, G., Mansfield, J., Morgan, A.R., Mowat, C., Newman, W., Palmieri, O., Ponsioen, C.Y., Potocnik, U., Prescott, N.J., Regueiro, M., Rotter, J.I., Russell, R.K., Sanderson, J.D., Sans, M., Satsangi, J., Schreiber, S., Simms, L.A., Sventoraityte, J., Targan, S.R., Taylor, K.D., Tremelling, M., Verspaget, H.W., De Vos, M., Wijmenga, C., Wilson, D.C., Winkelmann, J., Xavier, R.J., Zeissig, S., Zhang, B., Zhang, C.K., Zhao, H., Silverberg, M.S., Annese, V., Hakonarson, H., Brant, S.R., Radford-Smith, G., Mathew, C.G., Rioux, J.D., Schadt, E.E., Daly, M.J., Franke, A., Parkes, M., Vermeire, S., Barrett, J.C., Cho, J.H., Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:7422 (2012), 119–124.
13. Fowler, S.A., Ananthakrishnan, A.N., Gardet, A., Stevens, C.R., Korzenik, J.R., Sands, B.E., Daly, M.J., Xavier, R.J., Yajnik, V., SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. J. Crohn's and Colitis 8:8 (2014), 845–851.
14. Ardizzone, S., Bevivino, G., Monteleone, G., Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease. Therap. Adv.Gastroenterol 9:4 (2016), 527–532.
15. Asano, Y., Ihn, H., Yamane, K., Kubo, M., Tamaki, K., Impaired Smad7-Smurf–mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J. Clin. Invest., 113(2), 2004, 253.
16. Kim, S.W., Kim, E.S., Moon, C.M., Park, J.J., Kim, T.I., Kim, W.H., Cheon, J.H., Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease. Gut 60:11 (2011), 1527–1536.
17. O'Shea, J.J., Paul, W.E., Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327:5969 (2010), 1098–1102.
18. Coskun, M., Salem, M., Pedersen, J., Nielsen, O.H., Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol. Res. 76 (2013), 1–8.
19. Russo, C., Polosa, R., TNF-α as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin. Sci. 109:2 (2005), 135–142.
20. Potgieter, M., Bester, J., Kell, D.B., Pretorius, E., The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol. Rev. 39:4 (2015), 567–591.
21. Hansson, G.C., Role of mucus layers in gut infection and inflammation. Curr. Opin. Microbiol. 15:1 (2012), 57–62.
22. Ostaff, M.J., Stange, E.F., Wehkamp, J., Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol. Med. 5:10 (2013), 1465–1483.
23. Macpherson, A.J., Koller, Y., McCoy, K.D., The bilateral responsiveness between intestinal microbes and IgA. Trends Immunol. 36:8 (2015), 460–470.
24. Sanjabi, S., Zenewicz, L.A., Kamanaka, M., Flavell, R.A., Anti-inflammatory and pro-inflammatory roles of TGF-β IL-10, and IL-22 in immunity and autoimmunity. Curr. Opin. Pharmacol. 9:4 (2009), 447–453.
25. Cobo, E., Chadee, K., Antimicrobial human β-defensins in the colon and their role in infectious and non-infectious diseases. Pathogens, 2(1), 2013, 177.
26. Maloy, K.J., Powrie, F., Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474:7351 (2011), 298–306.
27. Steinbach, E.C., Plevy, S.E., The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm. Bowel Dis. 20:1 (2014), 166–175.
28. Liu, Z.M., Wang, K.P., Ma, J., Guo Zheng, S., The role of all-trans retinoic acid in the biology of Foxp3+ regulatory T cells. Cell. Mol. Immunol. 12:5 (2015), 553–557.
29. Ciofani, M., Madar, A., Galan, C., Sellars, M., Mace, K., Pauli, F., Agarwal, A., Huang, W., Parkhurst, C.N., Muratet, M., Newberry, K.M., Meadows, S., Greenfield, A., Yang, Y., Jain, P., Kirigin, F.K., Birchmeier, C., Wagner, E.F., Murphy, K.M., Myers, R.M., Bonneau, R., Littman, D.R., A validated regulatory network for Th17 cell specification. Cell 151:2 (2012), 289–303.
30. Basu, R., Hatton, R.D., Weaver, C.T., The Th17 family: flexibility follows function. Immunol. Rev. 252:1 (2013), 89–103.
31. Lee, Y.K., Turner, H., Maynard, C.L., Oliver, J.R., Chen, D., Elson, C.O., Weaver, C.T., Late developmental plasticity in the T helper 17 lineage. Immunity 30:1 (2009), 92–107.
32. Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E., Fili, L., Ferri, S., Frosali, F., Giudici, F., Romagnani, P., Parronchi, P., Tonelli, F., Maggi, E., Romagnani, S., Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204:8 (2007), 1849–1861.
33. Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M., Weaver, C.T., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:11 (2005), 1123–1132.
34. Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., Gurney, A.L., Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:3 (2003), 1910–1914.
35. Ahern, P.P., Schiering, C., Buonocore, S., McGeachy, M.J., Cua, D.J., Maloy, K.J., Powrie, F., Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33:2 (2010), 279–288.
36. Cosmi, L., Maggi, L., Santarlasci, V., Capone, M., Cardilicchia, E., Frosali, F., Querci, V., Angeli, R., Matucci, A., Fambrini, M., Liotta, F., Parronchi, P., Maggi, E., Romagnani, S., Annunziato, F., Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J. Allergy Clin. Immunol., 125(1), 2010 222-30 e1–4.
37. Saraiva, M., O'Garra, A., The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10:3 (2010), 170–181.
38. Evans, H.G., Roostalu, U., Walter, G.J., Gullick, N.J., Frederiksen, K.S., Roberts, C.A., Sumner, J., Baeten, D.L., Gerwien, J.G., Cope, A.P., Geissmann, F., Kirkham, B.W., Taams, L.S., TNF-alpha blockade induces IL-10 expression in human CD4+ T cells. Nat. Commun., 5, 2014, 3199.
39. Esplugues, E., Huber, S., Gagliani, N., Hauser, A.E., Town, T., Wan, Y.Y., O'Connor, W. Jr., Rongvaux, A., Van Rooijen, N., Haberman, A.M., Iwakura, Y., Kuchroo, V.K., Kolls, J.K., Bluestone, J.A., Herold, K.C., Flavell, R.A., Control of TH17 cells occurs in the small intestine. Nature 475:7357 (2011), 514–518.
40. Gagliani, N., Magnani, C.F., Huber, S., Gianolini, M.E., Pala, M., Licona-Limon, P., Guo, B., Herbert, D.R., Bulfone, A., Trentini, F., Di Serio, C., Bacchetta, R., Andreani, M., Brockmann, L., Gregori, S., Flavell, R.A., Roncarolo, M.G., Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat. Med. 19:6 (2013), 739–746.
41. Bhaumik, S., Basu, R., Cellular, Molecular dynamics of Th17 differentiation and its developmental plasticity in the intestinal immune response. Front. Immunol., 8, 2017, 254.
42. Wang, C., Collins, M., Kuchroo, V.K., Effector T cell differentiation: are master regulators of effector T cells still the masters?. Curr. Opin. Immunol. 37 (2015), 6–10.
43. Ueno, A., Ghosh, A., Hung, D., Li, J., Jijon, H., Th17 plasticity and its changes associated with inflammatory bowel disease. World J. Gastroenterol. 21:43 (2015), 12283–12295.
44. Hovhannisyan, Z., Treatman, J., Littman, D.R., Mayer, L., Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140:3 (2011), 957–965.
45. Ueno, A., Jijon, H., Chan, R., Ford, K., Hirota, C., Kaplan, G.G., Beck, P.L., Iacucci, M., Fort Gasia, M., Barkema, H.W., Panaccione, R., Ghosh, S., Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm. Bowel Dis. 19:12 (2013), 2522–2534.
46. Lee, Y.K., Mukasa, R., Hatton, R.D., Weaver, C.T., Developmental plasticity of Th17 and Treg cells. Curr. Opin. Immunol. 21:3 (2009), 274–280.
47. Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E., Filì L., Ferri, S., Frosali, F., Giudici, F., Romagnani, P., Parronchi, P., Tonelli, F., Maggi, E., Romagnani, S., Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204:8 (2007), 1849–1861.
48. Hirota, K., Duarte, J.H., Veldhoen, M., Hornsby, E., Li, Y., Cua, D.J., Ahlfors, H., Wilhelm, C., Tolaini, M., Menzel, U., Garefalaki, A., Potocnik, A.J., Stockinger, B., Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12:3 (2011), 255–263.
49. Kobayashi, T., Okamoto, S., Hisamatsu, T., Kamada, N., Chinen, H., Saito, R., Kitazume, M.T., Nakazawa, A., Sugita, A., Koganei, K., Isobe, K., Hibi, T., IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57:12 (2008), 1682–1689.
50. Cosmi, L., De Palma, R., Santarlasci, V., Maggi, L., Capone, M., Frosali, F., Rodolico, G., Querci, V., Abbate, G., Angeli, R., Berrino, L., Fambrini, M., Caproni, M., Tonelli, F., Lazzeri, E., Parronchi, P., Liotta, F., Maggi, E., Romagnani, S., Annunziato, F., Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med. 205:8 (2008), 1903–1916.
51. Tanoue, T., Atarashi, K., Honda, K., Development and maintenance of intestinal regulatory T cells. Nat. Rev. Immunol. 16:5 (2016), 295–309.
52. Koch, M.A., Tucker-Heard, G.s., Perdue, N.R., Killebrew, J.R., Urdahl, K.B., Campbell, D.J., The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 10:6 (2009), 595–602.
53. Wohlfert, E.A., Grainger, J.R., Bouladoux, N., Konkel, J.E., Oldenhove, G., Ribeiro, C.H., Hall, J.A., Yagi, R., Naik, S., Bhairavabhotla, R., Paul, W.E., Bosselut, R., Wei, G., Zhao, K., Oukka, M., Zhu, J., Belkaid, Y., GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. J. Clin. Invest. 121:11 (2011), 4503–4515.
54. Rudra, D., deRoos, P., Chaudhry, A., Niec, R.E., Arvey, A., Samstein, R.M., Leslie, C., Shaffer, S.A., Goodlett, D.R., Rudensky, A.Y., Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat. Immunol. 13:10 (2012), 1010–1019.
55. Yu, F., Sharma, S., Edwards, J., Feigenbaum, L., Zhu, J., Dynamic expression of transcription factors T-bet and GATA-3 by regulatory T cells maintains immunotolerance. Nat. Immunol. 16:2 (2015), 197–206.
56. Zhou, L., Lopes, J.E., Chong, M.M., Ivanov, I.I., Min, R., Victora, G.D., Shen, Y., Du, J., Rubtsov, Y.P., Rudensky, A.Y., Ziegler, S.F., Littman, D.R., TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453:7192 (2008), 236–240.
57. Li, J., Ueno, A., Iacucci, M., Fort Gasia, M., Jijon, H.B., Panaccione, R., Kaplan, G.G., Beck, P.L., Luider, J., Barkema, H.W., Qian, J., Gui, X., Ghosh, S., Crossover subsets of CD4+ T lymphocytes in the intestinal lamina propria of patients with Crohn's disease and ulcerative colitis. Dig. Dis. Sci., 2017.
58. Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., Cua, D.J., Littman, D.R., The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:6 (2006), 1121–1133.
59. Ichiyama, K., Yoshida, H., Wakabayashi, Y., Chinen, T., Saeki, K., Nakaya, M., Takaesu, G., Hori, S., Yoshimura, A., Kobayashi, T., Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J. Biol. Chem. 283:25 (2008), 17003–17008.
60. Veldhoen, M., Stockinger, B., TGFbeta1, a “Jack of all trades”: the link with pro-inflammatory IL-17-producing T cells. Trends Immunol. 27:8 (2006), 358–361.
61. Yang, X.O., Pappu, B.P., Nurieva, R., Akimzhanov, A., Kang, H.S., Chung, Y., Ma, L., Shah, B., Panopoulos, A.D., Schluns, K.S., Watowich, S.S., Tian, Q., Jetten, A.M., Dong, C., T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28:1 (2008), 29–39.
62. Li, L.-J., Gong, C., Zhao, M.-H., Feng, B.-S., Role of interleukin-22 in inflammatory bowel disease. World J. Gastroenterol. : WJG 20:48 (2014), 18177–18188.
63. Sonnenberg, G.F., Fouser, L.A., Artis, D., Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12:5 (2011), 383–390.
64. Davenport, M., Poles, J., Leung, J.M., Wolff, M.J., Abidi, W.M., Ullman, T., Mayer, L., Cho, I., Loke, P., Metabolic alterations to the mucosal microbiota in inflammatory bowel disease. Inflamm. Bowel Dis. 20:4 (2014), 723–731.
65. Leung, J.M., Davenport, M., Wolff, M.J., Wiens, K.E., Abidi, W.M., Poles, M.A., Cho, I., Ullman, T., Mayer, L., Loke, P., IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol. 7:1 (2014), 124–133.
66. Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J.P., Eberl, G., Koyasu, S., Locksley, R.M., McKenzie, A.N., Mebius, R.E., Powrie, F., Vivier, E., Innate lymphoid cells–a proposal for uniform nomenclature. Nat. Rev. Immunol. 13:2 (2013), 145–149.
67. S. Wang, P. Xia, Y. Chen, Y. Qu, Z. Xiong, B. Ye, Y. Du, Y. Tian, Z. Yin, Z. Xu, Z. Fan, Regulatory innate lymphoid cells control innate intestinal inflammation, Cell 171(1) 201–216.e18.
68. Shikhagaie, M.M., Germar, K., Bal, S.M., Ros, X.R., Spits, H., Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases. Nat. Rev. Rheumatol. 13:3 (2017), 164–173.
69. Forkel, M., Mjosberg, J., Dysregulation of group 3 innate lymphoid cells in the pathogenesis of inflammatory bowel disease. Curr. Allergy Asthma Rep., 16(10), 2016, 73.
70. Geremia, A., Arancibia-Carcamo, C.V., Innate lymphoid cells in intestinal inflammation. Front. Immunol., 8, 2017, 1296.
71. Lim, A.I., Menegatti, S., Bustamante, J., Le Bourhis, L., Allez, M., Rogge, L., Casanova, J.L., Yssel, H., Di Santo, J.P., IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J. Exp. Med. 213:4 (2016), 569–583.
72. Pearson, C., Uhlig, H.H., Powrie, F., Lymphoid microenvironments and innate lymphoid cells in the gut. Trends Immunol. 33:6 (2012), 289–296.
73. Matsuoka, K., Inoue, N., Sato, T., Okamoto, S., Hisamatsu, T., Kishi, Y., Sakuraba, A., Hitotsumatsu, O., Ogata, H., Koganei, K., Fukushima, T., Kanai, T., Watanabe, M., Ishii, H., Hibi, T., T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut 53:9 (2004), 1303–1308.
74. Li, S., Heller, J.J., Bostick, J.W., Lee, A., Schjerven, H., Kastner, P., Chan, S., Chen, Z.E., Zhou, L., Ikaros inhibits group 3 innate lymphoid cell development and function by suppressing the aryl hydrocarbon receptor pathway. Immunity 45:1 (2016), 185–197.
75. Tom, M.R., Li, J., Ueno, A., Fort Gasia, M., Chan, R., Hung, D.Y., Chenoo, S., Iacucci, M., Jijon, H.B., Kaplan, G.G., Beck, P.L., Panaccione, R., Barkema, H.W., Buret, A.G., Yajnik, V., Ghosh, S., Novel CD8+ t-cell subsets demonstrating plasticity in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 22:7 (2016), 1596–1608.
76. John, L.B., Ward, A.C., The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. Mol. Immunol. 48:9–10 (2011), 1272–1278.
77. McGovern, D.P., Kugathasan, S., Cho, J.H., Genetics of inflammatory bowel diseases. Gastroenterology, 149(5), 2015 1163–1176 e2.
78. Petukhova, L., Duvic, M., Hordinsky, M., Norris, D., Price, V., Shimomura, Y., Kim, H., Singh, P., Lee, A., Chen, W.V., Meyer, K.C., Paus, R., Jahoda, C.A., Amos, C.I., Gregersen, P.K., Christiano, A.M., Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466:7302 (2010), 113–117.
79. Lempainen, J., Harkonen, T., Laine, A., Knip, M., Ilonen, J., Associations of polymorphisms in non-HLA loci with autoantibodies at the diagnosis of type 1 diabetes: INS and IKZF4 associate with insulin autoantibodies. Pediatr. Diabetes 14:7 (2013), 490–496.
80. Wong, L.Y., Hatfield, J.K., Brown, M.A., Ikaros sets the potential for Th17 lineage gene expression through effects on chromatin state in early T cell development. J. Biol. Chem. 288:49 (2013), 35170–35179.
81. Heller, J.J., Schjerven, H., Li, S., Lee, A., Qiu, J., Chen, Z.M., Smale, S.T., Zhou, L., Restriction of IL-22-producing T cell responses and differential regulation of regulatory T cell compartments by zinc finger transcription factor Ikaros. J. Immunol. 193:8 (2014), 3934–3946.
82. Thornton, A.M., Korty, P.E., Tran, D.Q., Wohlfert, E.A., Murray, P.E., Belkaid, Y., Shevach, E.M., Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184:7 (2010), 3433–3441.
83. Himmel, M.E., MacDonald, K.G., Garcia, R.V., Steiner, T.S., Levings, M.K., Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J. Immunol. 190:5 (2013), 2001–2008.
84. Akimova, T., Beier, U.H., Wang, L., Levine, M.H., Hancock, W.W., Helios expression is a marker of T cell activation and proliferation. PLos One, 6(8), 2011, e24226.
85. Gottschalk, R.A., Corse, E., Allison, J.P., Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J. Immunol. 188:3 (2012), 976–980.
86. Raffin, C., Pignon, P., Celse, C., Debien, E., Valmori, D., Ayyoub, M., Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1beta by downregulating their suppressor functions. J. Immunol. 191:9 (2013), 4619–4627.
87. Alexander, T., Sattler, A., Templin, L., Kohler, S., Gross, C., Meisel, A., Sawitzki, B., Burmester, G.R., Arnold, R., Radbruch, A., Thiel, A., Hiepe, F., Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann. Rheum. Dis. 72:9 (2013), 1549–1558.
88. Muller, M., Herrath, J., Malmstrom, V., IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint. Clin. Exp. Immunol. 182:1 (2015), 90–100.
89. Quintana, F.J., Jin, H., Burns, E.J., Nadeau, M., Yeste, A., Kumar, D., Rangachari, M., Zhu, C., Xiao, S., Seavitt, J., Georgopoulos, K., Kuchroo, V.K., Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat. Immunol. 13:8 (2012), 770–777.
90. Gandhi, A.K., Kang, J., Havens, C.G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M.F., Thakurta, A., Klippel, A., Handa, H., Daniel, T.O., Schafer, P.H., Chopra, R., Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br. J. Haematol. 164:6 (2014), 811–821.
91. Pan, F., Yu, H., Dang, E.V., Barbi, J., Pan, X., Grosso, J.F., Jinasena, D., Sharma, S.M., McCadden, E.M., Getnet, D., Drake, C.G., Liu, J.O., Ostrowski, M.C., Pardoll, D.M., Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (New York, N.Y 325:5944 (2009), 1142–1146.
92. Sharma, M.D., Huang, L., Choi, J.H., Lee, E.J., Wilson, J.M., Lemos, H., Pan, F., Blazar, B.R., Pardoll, D.M., Mellor, A.L., Shi, H., Munn, D.H., An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity 38:5 (2013), 998–1012.
93. Rieder, S.A., Metidji, A., Glass, D.D., Thornton, A.M., Ikeda, T., Morgan, B.A., Shevach, E.M., Eos is redundant for regulatory T cell function but plays an important role in IL-2 and Th17 production by CD4+ conventional T cells. J. Immunol. 195:2 (2015), 553–563.
94. Ukena, S.N., Geffers, R., Buchholz, S., Stadler, M., Franzke, A., Biomarkers for acute and chronic graft-versus-host disease in regulatory T cells. Transpl. Immunol. 27:4 (2012), 179–183.
95. Liu, S.Q., Jiang, S., Li, C., Zhang, B., Li, Q.J., miR-17-92 cluster targets phosphatase and tensin homology and Ikaros Family Zinc Finger 4 to promote TH17-mediated inflammation. J. Biol. Chem. 289:18 (2014), 12446–12456.
96. Yang, B.H., Hagemann, S., Mamareli, P., Lauer, U., Hoffmann, U., Beckstette, M., Fohse, L., Prinz, I., Pezoldt, J., Suerbaum, S., Sparwasser, T., Hamann, A., Floess, S., Huehn, J., Lochner, M., Foxp3(+) T cells expressing RORgammat represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation. Mucosal Immunol. 9:2 (2016), 444–457.
97. Lochner, M., Berard, M., Sawa, S., Hauer, S., Gaboriau-Routhiau, V., Fernandez, T.D., Snel, J., Bousso, P., Cerf-Bensussan, N., Eberl, G., Restricted microbiota and absence of cognate TCR antigen leads to an unbalanced generation of Th17 cells. J. Immunol. 186:3 (2011), 1531–1537.
98. Ohnmacht, C., Park, J.H., Cording, S., Wing, J.B., Atarashi, K., Obata, Y., Gaboriau-Routhiau, V., Marques, R., Dulauroy, S., Fedoseeva, M., Busslinger, M., Cerf-Bensussan, N., Boneca, I.G., Voehringer, D., Hase, K., Honda, K., Sakaguchi, S., Eberl, G., MUCOSAL IMMUNOLOGY. The microbiota regulates type 2 immunity through RORgammat(+) T cells. Science 349:6251 (2015), 989–993.
99. Sefik, E., Geva-Zatorsky, N., Oh, S., Konnikova, L., Zemmour, D., McGuire, A.M., Burzyn, D., Ortiz-Lopez, A., Lobera, M., Yang, J., Ghosh, S., Earl, A., Snapper, S.B., Jupp, R., Kasper, D., Mathis, D., Benoist, C., MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science 349:6251 (2015), 993–997.
100. Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., Taniguchi, T., Takeda, K., Hori, S., Ivanov, I.I., Umesaki, Y., Itoh, K., Honda, K., Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331:6015 (2011), 337–341.
101. Narushima, S., Sugiura, Y., Oshima, K., Atarashi, K., Hattori, M., Suematsu, M., Honda, K., Characterization of the 17 strains of regulatory T cell-inducing human-derived Clostridia. Gut Microb. 5:3 (2014), 333–339.
102. Ivanov, I.I., Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K.C., Santee, C.A., Lynch, S.V., Tanoue, T., Imaoka, A., Itoh, K., Takeda, K., Umesaki, Y., Honda, K., Littman, D.R., Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:3 (2009), 485–498.
103. Uematsu, S., Akira, S., Toll-like receptors and innate immunity. J. Mol. Med. 84:9 (2006), 712–725.
104. Prakash, T., Oshima, K., Morita, H., Fukuda, S., Imaoka, A., Kumar, N., Sharma, V.K., Kim, S.W., Takahashi, M., Saitou, N., Taylor, T.D., Ohno, H., Umesaki, Y., Hattori, M., Complete genome sequences of rat and mouse segmented filamentous bacteria, a potent inducer of th17 cell differentiation. Cell Host Microbe 10:3 (2011), 273–284.
105. Kinnebrew, M.A., Buffie, C.G., Diehl, G.E., Zenewicz, L.A., Leiner, I., Hohl, T.M., Flavell, R.A., Littman, D.R., Pamer, E.G., Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity 36:2 (2012), 276–287.
106. Zielinski, C.E., Mele, F., Aschenbrenner, D., Jarrossay, D., Ronchi, F., Gattorno, M., Monticelli, S., Lanzavecchia, A., Sallusto, F., Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 484:7395 (2012), 514–518.
107. Gagliardi, M.C., Teloni, R., Mariotti, S., Bromuro, C., Chiani, P., Romagnoli, G., Giannoni, F., Torosantucci, A., Nisini, R., Endogenous PGE2 promotes the induction of human Th17 responses by fungal ss-glucan. J. Leukoc. Biol. 88:5 (2010), 947–954.
108. Lee, S.J., McLachlan, J.B., Kurtz, J.R., Fan, D., Winter, S.E., Baumler, A.J., Jenkins, M.K., McSorley, S.J., Temporal expression of bacterial proteins instructs host CD4 T cell expansion and Th17 development. PLoS Pathog., 8(1), 2012, e1002499.
109. Galvez, J., Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm., 2014, 2014, 928461.
110. Torchinsky, M.B., Garaude, J., Martin, A.P., Blander, J.M., Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature 458:7234 (2009), 78–82.
111. Kunisawa, J., Kiyono, H., Vitamin-mediated regulation of intestinal immunity. Front. Immunol., 4, 2013, 189.
112. Coombes, J.L., Siddiqui, K.R., Arancibia-Carcamo, C.V., Hall, J., Sun, C.M., Belkaid, Y., Powrie, F., A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 204:8 (2007), 1757–1764.
113. Iliev, I.D., Spadoni, I., Mileti, E., Matteoli, G., Sonzogni, A., Sampietro, G.M., Foschi, D., Caprioli, F., Viale, G., Rescigno, M., Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut 58:11 (2009), 1481–1489.
114. Magnusson, M.K., Brynjolfsson, S.F., Dige, A., Uronen-Hansson, H., Borjesson, L.G., Bengtsson, J.L., Gudjonsson, S., Ohman, L., Agnholt, J., Sjovall, H., Agace, W.W., Wick, M.J., Macrophage and dendritic cell subsets in IBD: ALDH+ cells are reduced in colon tissue of patients with ulcerative colitis regardless of inflammation. Mucosal Immunol. 9:1 (2016), 171–182.
115. Brown, C.C., Esterhazy, D., Sarde, A., London, M., Pullabhatla, V., Osma-Garcia, I., Al-Bader, R., Ortiz, C., Elgueta, R., Arno, M., de Rinaldis, E., Mucida, D., Lord, G.M., Noelle, R.J., Retinoic acid is essential for Th1 cell lineage stability and prevents transition to a Th17 cell program. Immunity 42:3 (2015), 499–511.
116. Urry, Z., Chambers, E.S., Xystrakis, E., Dimeloe, S., Richards, D.F., Gabrysova, L., Christensen, J., Gupta, A., Saglani, S., Bush, A., O'Garra, A., Brown, Z., Hawrylowicz, C.M., The role of 1alpha,25-dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+ and IL-10+ CD4+ T cells. Eur. J. Immunol. 42:10 (2012), 2697–2708.
117. Barrat, F.J., Cua, D.J., Boonstra, A., Richards, D.F., Crain, C., Savelkoul, H.F., Waal-Malefyt, R., Coffman, R.L., Hawrylowicz, C.M., O'Garra, A., In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195:5 (2002), 603–616.
118. Jeffery, L.E., Burke, F., Mura, M., Zheng, Y., Qureshi, O.S., Hewison, M., Walker, L.S., Lammas, D.A., Raza, K., Sansom, D.M., 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 183:9 (2009), 5458–5467.
119. Kang, S.W., Kim, S.H., Lee, N., Lee, W.W., Hwang, K.A., Shin, M.S., Lee, S.H., Kim, W.U., Kang, I., 1,25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J. Immunol. 188:11 (2012), 5276–5282.
120. Colin, E.M., Asmawidjaja, P.S., van Hamburg, J.P., Mus, A.M., van Driel, M., Hazes, J.M., van Leeuwen, J.P., Lubberts, E., 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum. 62:1 (2010), 132–142.
121. Piet van Hamburg, J., Asmawidjaja, P.S., Davelaar, N., Cornelissen, F.C., Mus, A.M., Bakx, P.A., Colin, E.M., van Leeuwen, H., Hazes, J.M., Dolhain, R.J., Lubberts, E., Vitamin D suppresses the pathogenic behaviour of primary Th17 cells from patients with early rheumatoid arthritis. Ann. Rheum. Dis., 70(Suppl 2), 2011 A47–A47.
122. Ryz, N.R., Patterson, S.J., Zhang, Y., Ma, C., Huang, T., Bhinder, G., Wu, X., Chan, J., Glesby, A., Sham, H.P., Dutz, J.P., Levings, M.K., Jacobson, K., Vallance, B.A., Active vitamin D (1,25-dihydroxyvitamin D3) increases host susceptibility to Citrobacter rodentium by suppressing mucosal Th17 responses, American journal of physiology. Gastrointest. Liver Physiol. 303:12 (2012), G1299–G1311.
123. Jeffery, L.E., Qureshi, O.S., Gardner, D., Hou, T.Z., Briggs, Z., Soskic, B., Baker, J., Raza, K., Sansom, D.M., Vitamin D antagonises the suppressive effect of inflammatory cytokines on CTLA-4 expression and regulatory function. PLos One, 10(7), 2015, e0131539.
124. O'Sullivan, M., Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?. Proc. Nutr. Soc. 74:1 (2015), 5–12.
125. Raman, M., Milestone, A.N., Walters, J.R.F., Hart, A.L., Ghosh, S., Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer. Therap. Adv.Gastroenterol 4:1 (2011), 49–62.
126. Hlavaty, T., Krajcovicova, A., Payer, J., Vitamin D therapy in inflammatory bowel diseases: who, in what form, and how much?. J. Crohn's & colitis 9:2 (2015), 198–209.
127. Cantorna, M.T., Munsick, C., Bemiss, C., Mahon, B.D., 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J. Nutr. 130:11 (2000), 2648–2652.
128. Froicu, M., Weaver, V., Wynn, T.A., McDowell, M.A., Welsh, J.E., Cantorna, M.T., A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol. Endocrinol. 17:12 (2003), 2386–2392.
129. Ananthakrishnan, A.N., Khalili, H., Konijeti, G.G., Higuchi, L.M., de Silva, P., Korzenik, J.R., Fuchs, C.S., Willett, W.C., Richter, J.M., Chan, A.T., A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 145:5 (2013), 970–977.
130. Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J.R., Pfeffer, K., Coffer, P.J., Rudensky, A.Y., Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504:7480 (2013), 451–455.
131. Schilderink, R., Verseijden, C., Seppen, J., Muncan, V., van den Brink, G.R., Lambers, T.T., van Tol, E.A., de Jonge, W.J., The SCFA butyrate stimulates the epithelial production of retinoic acid via inhibition of epithelial HDAC, American journal of physiology. Gastrointest. Liver Physiol. 310:11 (2016), G1138–G1146.
132. Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P.D., Manicassamy, S., Munn, D.H., Lee, J.R., Offermanns, S., Ganapathy, V., Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40:1 (2014), 128–139.
133. Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., Takahashi, M., Fukuda, N.N., Murakami, S., Miyauchi, E., Hino, S., Atarashi, K., Onawa, S., Fujimura, Y., Lockett, T., Clarke, J.M., Topping, D.L., Tomita, M., Hori, S., Ohara, O., Morita, T., Koseki, H., Kikuchi, J., Honda, K., Hase, K., Ohno, H., Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:7480 (2013), 446–450.
134. Luu, M., Steinhoff, U., Visekruna, A., Functional heterogeneity of gut-resident regulatory T cells. Clin. Translat. Immunol., 6(9), 2017, e156.
135. Trost, L.B., McDonnell, J.K., Important cutaneous manifestations of inflammatory bowel disease. Postgrad. Med. 81:959 (2005), 580–585.
136. Macia, L., Tan, J., Vieira, A.T., Leach, K., Stanley, D., Luong, S., Maruya, M., Ian McKenzie, C., Hijikata, A., Wong, C., Binge, L., Thorburn, A.N., Chevalier, N., Ang, C., Marino, E., Robert, R., Offermanns, S., Teixeira, M.M., Moore, R.J., Flavell, R.A., Fagarasan, S., Mackay, C.R., Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun., 6, 2015, 6734.
137. Lamas, B., Richard, M.L., Leducq, V., Pham, H.P., Michel, M.L., Da Costa, G., Bridonneau, C., Jegou, S., Hoffmann, T.W., Natividad, J.M., Brot, L., Taleb, S., Couturier-Maillard, A., Nion-Larmurier, I., Merabtene, F., Seksik, P., Bourrier, A., Cosnes, J., Ryffel, B., Beaugerie, L., Launay, J.M., Langella, P., Xavier, R.J., Sokol, H., CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 22:6 (2016), 598–605.
138. Mezrich, J.D., Fechner, J.H., Zhang, X., Johnson, B.P., Burlingham, W.J., Bradfield, C.A., An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185:6 (2010), 3190–3198.
139. Veldhoen, M., Hirota, K., Christensen, J., O'Garra, A., Stockinger, B., Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J. Exp. Med. 206:1 (2009), 43–49.
140. Veldhoen, M., Hirota, K., Westendorf, A.M., Buer, J., Dumoutier, L., Renauld, J.C., Stockinger, B., The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453:7191 (2008), 106–109.
141. Argollo, M., Fiorino, G., Hindryck, P., Peyrin-Biroulet, L., Danese, S., Novel therapeutic targets for inflammatory bowel disease. J. Autoimmun., 2017.
142. Hueber, W., Sands, B.E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P.D., Wehkamp, J., Feagan, B.G., Yao, M.D., Karczewski, M., Karczewski, J., Pezous, N., Bek, S., Bruin, G., Mellgard, B., Berger, C., Londei, M., Bertolino, A.P., Tougas, G., Travis, S.P., Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:12 (2012), 1693–1700.
143. Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., Mpofu, S., Richards, H.B., Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373:26 (2015), 2534–2548.
144. Langley, R.G., Elewski, B.E., Lebwohl, M., Reich, K., Griffiths, C.E., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., Papavassilis, C., Secukinumab in plaque psoriasis–results of two phase 3 trials. N. Engl. J. Med. 371:4 (2014), 326–338.
145. Targan, S.R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G.Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., Chon, Y., Hsu, Y.H., Lin, S.L., Klekotka, P., A Randomized, Double-Blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. Am. J. Gastroenterol. 111:11 (2016), 1599–1607.
146. Kaser, A., Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease, Best practice & research. Clin. Gastroenterol. 28:3 (2014), 437–449.
147. Feagan, B.G., Sandborn, W.J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J.R., Blank, M.A., Johanns, J., Gao, L.L., Miao, Y., Adedokun, O.J., Sands, B.E., Hanauer, S.B., Vermeire, S., Targan, S., Ghosh, S., de Villiers, W.J., Colombel, J.F., Tulassay, Z., Seidler, U., Salzberg, B.A., Desreumaux, P., Lee, S.D., Loftus, E.V. Jr., Dieleman, L.A., Katz, S., Rutgeerts, P., Ustekinumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 375:20 (2016), 1946–1960.
148. Okamoto, S., Fujiwara, H., Nishimori, H., Matsuoka, K., Fujii, N., Kondo, E., Tanaka, T., Yoshimura, A., Tanimoto, M., Maeda, Y., Anti-IL-12/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-gamma/IL-17-producing cells. J. Immunol. 194:3 (2015), 1357–1363.
149. Kontzias, A., Kotlyar, A., Laurence, A., Changelian, P., O'Shea, J.J., Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr. Opin. Pharmacol. 12:4 (2012), 464–470.
150. Monteleone, G., Neurath, M.F., Ardizzone, S., Di Sabatino, A., Fantini, M.C., Castiglione, F., Scribano, M.L., Armuzzi, A., Caprioli, F., Sturniolo, G.C., Rogai, F., Vecchi, M., Atreya, R., Bossa, F., Onali, S., Fichera, M., Corazza, G.R., Biancone, L., Savarino, V., Pica, R., Orlando, A., Pallone, F., Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N. Engl. J. Med. 372:12 (2015), 1104–1113.
151. Tanaka, T., Narazaki, M., Kishimoto, T., Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 585:23 (2011), 3699–3709.